Fig. 3

MGMTpromoter methylation trends in DNA methylation array samples. (A) Frequency of positive results for all glioma array samples above and below the cutoff of VAF = 0.245. (B) Cumulative mean frequency of positive results for all glioma array samples as a function of VAF. (C) Frequency of positive results for GBM array samples above and below the cutoff of TERT VAF = 0.325. (D) Cumulative mean frequency of positive results in GBM array samples as a function of TERT VAF. (E) Frequency of positive results in GBM pyrosequencing samples using MGMT cutoff of 10.0% versus GBM array samples. (F) Frequency of positive results in GBM pyrosequencing samples using MGMT cutoff of 7.28% versus GBM array samples. (G) Frequency of positive results in GBM pyrosequencing samples with TERT VAF < 0.115, using MGMT cutoff of 7.28%, versus GBM array samples with TERT VAF < 0.325. (H) Frequency of positive results in GBM pyrosequencing samples with TERT VAF ≥ 0.115, using MGMT cutoff of 7.28%, versus GBM array samples with TERT VAF ≥ 0.325. (I) Frequency of positive results for IDHmut astrocytoma above and below the cutoff of IDH VAF = 0.325 (left), by methylation class match (center), and above and below the cutoff of classifier score = 0.955 (right). (J) Cumulative mean frequency of positive results in IDHmut astrocytoma array samples as a function of IDH VAF (Fisher’s exact test for panels A, C, E, F, G, H, I; GBM: IDH-wildtype glioblastoma, IDHmut astrocytoma: IDH-mutant astrocytoma)